Hepatitis B immunoglobulins and/or lamivudine for preventing hepatitis B recurrence after liver transplantation: A systematic review

Journal of Gastroenterology and Hepatology (Australia)

Volumn 25, Issue 5, 2010, Pages 872-879

  Chen, Jie ^a   Yi, Liping ^a   Jia, Ji Dong ^a   Ma, Hong ^a   You, Hong ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

Hepatitis B immunoglobulins; Hepatitis B recurrence; Lamivudine; Liver transplantation; Systematic review

Indexed keywords

HEPATITIS B ANTIBODY; HEPATITIS B ANTIBODY PLUS LAMIVUDINE; HEPATITIS B SURFACE ANTIGEN; LAMIVUDINE; UNCLASSIFIED DRUG; ANTIVIRUS AGENT; HEPATITIS B HYPERIMMUNE GLOBULIN; IMMUNOGLOBULIN;

ARTICLE; CLINICAL TRIAL; DATA BASE; DECOMPENSATED LIVER CIRRHOSIS; DRUG EFFICACY; DRUG MEGADOSE; EXPLORATORY RESEARCH; FOLLOW UP; HEPATITIS B; HUMAN; IMMUNOPROPHYLAXIS; LIVER FAILURE; LIVER TRANSPLANTATION; LONG TERM CARE; LOW DRUG DOSE; META ANALYSIS; MONOTHERAPY; MULTIVARIATE ANALYSIS; OUTCOME ASSESSMENT; PREDICTOR VARIABLE; PRIORITY JOURNAL; QUALITATIVE ANALYSIS; QUALITY CONTROL; RECURRENT DISEASE; SYSTEMATIC REVIEW; TREATMENT DURATION; INFECTION PREVENTION; INFECTION RISK; MULTICENTER STUDY (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENCE RISK; DRUG ADMINISTRATION; DRUG COMBINATION; RISK ASSESSMENT; RISK FACTOR; SECONDARY PREVENTION; TIME; TREATMENT OUTCOME;

ANTIVIRAL AGENTS; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; HEPATITIS B; HUMANS; IMMUNOGLOBULINS; LAMIVUDINE; LIVER TRANSPLANTATION; RISK ASSESSMENT; RISK FACTORS; SECONDARY PREVENTION; TIME FACTORS; TREATMENT OUTCOME;

EID: 77951737280     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2009.06151.x     Document Type: Article

References (68)

1. Lai CL, Ratziu V, Yuen MF, Poynard T. Viral hepatitis B. Lancet 2003 362 : 2089 2094.
2. Lee WM. Hepatitis B virus infection. N. Engl. J. Med. 1997 337 : 1733 1745.
3. Eason JD, Freeman RB, Rohrer RJ et al. Should liver transplantation be performed for patients with hepatitis B? Transplantation 1994 57 : 1588 1593.
4. Todo S, Demetris AJ, Van Thiel D, Teperman L, Fung J, Starzl TE. Orthotopic liver transplantation for patients with hepatitis B virus related liver disease. Hepatology 1991 13 : 619 626.
5. O'Grady JG, Smith HM, Davies SE et al. Hepatitis B virus re-infection after orthotopic liver transplantation. Serological and clinical implications. J. Hepatol. 1992 14 : 104 111.
6. Johnson PJ, Wansbrough-Jones MH, Portmann B et al. Familial HBsAg-positive hepatoma: treatment with orthotopic liver transplantation and specific immunoglobulin. BMJ 1978 1 : 216.
7. Terrault N, Roche B, Samuel D. Management of the hepatitis B virus in the liver transplantation setting: a European and an American perspective. Liver Transpl. 2005 11 : 716 732.
8. Moher D, Pham B, Jones A et al. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses? Lancet 1998 352 : 609 613. (Pubitemid 28380142)
9. Kjaergard LL, Villumsen J, Gluud C. Reported methodologic quality and discrepancies between large and small randomized trials in meta-analyses. Ann. Intern. Med. 2001 135 : 982 989.
10. Brok J, Buckley N, Gluud C. Interventions for paracetamol (acetaminophen) overdose. Cochrane Database Syst. Rev. 2006 2 : CD003328.
11. Lee KW, Lee SK, Joh JW et al. Comparison of the efficacy in prevention of hepatitis B virus recurrence after liver transplantation between HBIG and lamivudine. Transplant. Proc. 2001 33 : 3643 3644.
12. Park SJ, Paik SW, Choi MS et al. Is lamivudine with 1-week HBlg as effective as long-term high-dose HBlg in HBV prophylaxis after liver transplantation? Transplant. Proc. 2002 34 : 1252 1254.
13. Park SJ, Paik SW, Choi MS et al. Is lamivudine with one-week HBIg as effective as long-term high dose HBIg in the HBV prophylaxis after liver transplantation? J. Hepatol. 2001 34 (Suppl. 1 2A.
14. Gugenheim J, Baldini E, Ouzan D, Mouiel J. Absence of initial viral replication and long-term high dose immunoglobulin administration improve results of hepatitis B virus recurrence prophylaxis after liver transplantation. Transplant. Proc. 1997 29 : 517 518.
15. McGory RW, Ishitani MB, Oliveira WM et al. Improved outcome of orthotopic liver transplantation for chronic hepatitis B cirrhosis with aggressive passive immunization. Transplantation 1996 61 : 1358 1364.
16. So SK, Esquivel CO, Imperial JC, Garcia G et al. Does Asian race affect hepatitis B virus recurrence or survival following liver transplantation for hepatitis B cirrhosis? J. Gastroenterol. Hepatol. 1999 14 (Suppl. S48 52.
17. Golling M, Arnold JC, Rudek B et al. HBV prophylaxis: cost/benefit analysis following liver transplantation for HBV-positive liver cirrhosis. Transplant. Proc. 1998 30 : 3316 3317.
18. Samuel D, Bismuth A, Mathieu D et al. Passive immunoprophylaxis after liver transplantation in HBsAg-positive patients. Lancet 1991 337 : 813 815.
19. Lemmens HP, Langrehr JM, Blumhardt G et al. Outcome following orthotopic liver transplantation in HBsAg-positive patients using short- or long-term immunoprophylaxis. Transplant. Proc. 1994 26 : 3622 3623.
20. Konig V, Hopf U, Neuhaus P et al. Long-term follow-up of hepatitis B virus-infected recipients after orthotopic liver transplantation. Transplantation 1994 58 : 553 559. (Pubitemid 24289845)
21. Targhetta S, Villamil F, Inturri P et al. Protocol liver biopsies in long-term management of patients transplanted for hepatitis B-related liver disease. World J. Gastroenterol. 2006 12 : 1706 1712.
22. Chu CJ, Fontana RJ, Moore C et al. Outcome of liver transplantation for hepatitis B: report of a single center's experience. Liver Transpl. 2001 7 : 724 731.
23. Samuel D, Muller R, Alexander G et al. Liver transplantation in European patients with the hepatitis B surface antigen. N. Engl. J. Med. 1993 329 : 1842 1847.
24. Terrault NA, Zhou S, Combs C et al. Prophylaxis in liver transplant recipients using a fixed dosing schedule of hepatitis B immunoglobulin. Hepatology 1996 24 : 1327 1333.
25. Lerut JP, Donataccio M, Ciccarelli O et al. Liver transplantation and HBsAg-positive postnecrotic cirrhosis: adequate immunoprophylaxis and delta virus co-infection as the significant determinants of long-term prognosis. J. Hepatol. 1999 30 : 706 714.
26. Grazi GL, Mazziotti A, Sama C et al. Liver transplantation in HBsAg-positive HBV-DNA-negative cirrhotics: immunoprophylaxis and long-term outcome. Liver Transpl. Surg. 1996 2 : 418 425.
27. Perrillo RP, Wright T, Rakela J et al. A multicenter United States-Canadian trial to assess lamivudine monotherapy before and after liver transplantation for chronic hepatitis B. Hepatology 2001 33 : 424 432.
28. Lo CM, Cheung ST, Lai CL et al. Liver transplantation in Asian patients with chronic hepatitis B using lamivudine prophylaxis. Ann. Surg. 2001 233 : 276 281.
29. Xia J, Wang YG, Wang YM et al. Efficacy of lamivudine for prevention of hepatitis B virus reinfection after liver transplantation. Chin. J. Organ. Transplant. 2006 27 : 167 169.
30. Yan ML, Yan LN, Li B et al. Prophylactic effect of lamivudine monotherapy against hepatitis B recurrence following liver transplantation. Chin. J. Bases. Clin. General. Surg. 2006 13 : 205 208.
31. Mutimer D, Dusheiko G, Barrett C et al. Lamivudine without HBIg for prevention of graft reinfection by hepatitis B: long-term follow-up. Transplantation 2000 70 : 809 815.
32. Zheng S, Wu J, Wang W et al. Lamivudine as prophylaxis against hepatitis B virus reinfection following orthotopic liver transplantation. Chin. Med. J. 2002 82 : 445 448.
33. Wu YM, Ho MC, Hu RH et al. Effective long term prophylaxis of HBV reactivation after liver transplantation with Lamivudine and low dose hepatitis B immunoglobulin (hbig). Transplantation 2006 82 (1 Suppl. 2 448.
34. Yan ML, Yan LN, Li B et al. Intramuscular hepatitis B immune globulin combined with lamivudine in prevention of hepatitis B recurrence after liver transplantation. Hepat. Pancreat. Dis. Int. 2006 5 : 360 363.
35. Rosenau J, Bahr MJ, Tillmann HL et al. Lamivudine and low-dose hepatitis B immune globulin for prophylaxis of hepatitis B reinfection after liver transplantation possible role of mutations in the YMDD motif prior to transplantation as a risk factor for reinfection. J. Hepatol. 2001 34 : 895 902.
36. Lu MQ, Cai CJ, Zhao H, Yang Y, Chen GH. Prevention and treatment of hepatitis B virus reinfection after liver transplantation. Chin. J. Surg. 2006 44 : 742 744.
37. Angus PW, McCaughan GW, Gane EJ, Crawford DH, Harley H. Combination low-dose hepatitis B immune globulin and lamivudine therapy provides effective prophylaxis against posttransplantation hepatitis B. Liver Transpl. 2000 6 : 429 433.
38. Ferretti G, Merli M, Ginanni Corradini S et al. Low-dose intramuscular hepatitis B immune globulin and lamivudine for long-term prophylaxis of hepatitis B recurrence after liver transplantation. Transplant. Proc. 2004 36 : 535 538.
39. Ali H, Egawa H, Uryuhara K et al. Prevention of hepatitis B virus recurrence after living donor liver transplantation. Transplant. Proc. 2004 36 : 2764 2767. (Pubitemid 40036831)
40. Karasu Z, Ozacar T, Akyildiz M et al. Low-dose hepatitis B immune globulin and higher-dose lamivudine combination to prevent hepatitis B virus recurrence after liver transplantation. Antivir. Ther. 2004 9 : 921 927.
41. Karademir S, Astarcioglu H, Akarsu M et al. Prophylactic use of low-dose, on-demand, intramuscular hepatitis B immunoglobulin and lamivudine after liver transplantation. Transplant. Proc. 2006 38 : 579 583.
42. Wang ZQ, Fu ZR, Ding GS et al. Prevention of hepatitis B virus reinfection following orthotopic liver transplantation: report of 281 cases. J. Dig. Surg. 2006 5 : 26 9.
43. Gane EJ, Angus PW, Strasser S et al. Lamivudine plus low-dose hepatitis B immunoglobulin to prevent recurrent hepatitis B following liver transplantation. Gastroenterology 2007 132 : 931.
44. Zhou GW, Xiao WD, Wu WD et al. The use of Lamivudine combined with low-dosage hepatitis B immunoglobulin to prevent recurrence of hepatitis B virus after liver transplantation. J. Surg. Concepts. Pract. 2005 10 : 353 355.
45. Takaki A, Yagi T, Iwasaki Y et al. Short-term high-dose followed by long-term low-dose hepatitis B immunoglobulin and lamivudine therapy prevented recurrent hepatitis B after liver transplantation. Transplantation 2007 83 : 231 233.
46. Steinmuller T, Seehofer D, Rayes N et al. Increasing applicability of liver transplantation for patients with hepatitis B-related liver disease. Hepatology 2002 35 : 1528 1535. (Pubitemid 34966909)
47. Dumortier J, Chevallier P, Scoazec JY, Berger F, Boillot O. Combined lamivudine and hepatitis B immunoglobulin for the prevention of hepatitis B recurrence after liver transplantation: long-term results. Am. J. Transplant. 2003 3 : 999 1002.
48. Marzano A, Salizzoni M, Debernardi-Venon W et al. Prevention of hepatitis B virus recurrence after liver transplantation in cirrhotic patients treated with lamivudine and passive immunoprophylaxis. J. Hepatol. 2001 34 : 903 910.
49. Seehofer D, Rayes N, Naumann U et al. Preoperative antiviral treatment and postoperative prophylaxis in HBV-DNA positive patients undergoing liver transplantation. Transplantation 2001 72 : 1381 1385.
50. Ben-Ari Z, Mor E, Bar-Nathan N, Shaharabani E, Shapira Z, Tur-Kaspa R. Combination hepatitis B immune globulin and lamivudine versus hepatitis B immune globulin monotherapy in preventing recurrent hepatitis B virus infection in liver transplant recipients. Transplant. Proc. 2003 35 : 609 611.
51. Sousa JM, Pareja F, Serrano J et al. Comparison between levels of anti-HBS with a fixed administration dose of HBIG and a combination of HBIG and lamivudine for the prophylaxis of hepatitis B after liver transplantation. Transplant. Proc. 2003 35 : 723 724.
52. Marzano A, Gaia S, Ghisetti V et al. Viral load at the time of liver transplantation and risk of hepatitis B virus recurrence. Liver Transpl. 2005 11 : 402 409.
53. Zheng S, Chen Y, Liang T et al. Prevention of hepatitis B recurrence after liver transplantation using lamivudine or lamivudine combined with hepatitis B Immunoglobulin prophylaxis. Liver Transpl. 2006 12 : 253 258. (Pubitemid 43273784)
54. Wu LW, He XS, Zhu XF et al. Application of hepatitis B immunoglobulin in prevention of hepatitis B recurrence after liver transplantation. J. Trop. Med. 2006 6 : 788 790.
55. Xia Q, Peng ZH, Lu J et al. Low-dose hepatitis B Immunoglobulin combined with lamivudine preventing hepatitis B recurrence after liver transplantation. Chin. J. Organ. Transplant. 2004 25 : 53.
56. Zhu JP, Li L, Zhang TL et al. Intramuscularlow-dose hepatitis B Immunoglobulin combined with lamivudine for prophylaxis against hepatitis B recurrence after liver transplantation. J. Clin. Med. Pract. 2003 7 : 239 241.
57. Yoshida H, Kato T, Levi DM et al. Lamivudine monoprophylaxis for liver transplant recipients with non-replicating hepatitis B virus infection. Clin. Transplant. 2007 21 : 166 171.
58. Roche B, Feray C, Gigou M et al. HBV DNA persistence 10 years after liver transplantation despite successful anti-HBS passive immunoprophylaxis. Hepatology 2003 38 : 86 95.
59. Liaw YF, Leung N, Kao JH et al. Asian-Pacific Association for the Study of the Liver. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. Hepatol. Int. 2008 2 : 263 283.
60. Lo CM, Fung JT, Lau GK et al. Development of antibody to hepatitis B surface antigen after liver transplantation for chronic hepatitis B. Hepatology 2003 37 : 36 43.
61. Luo Y, Lo CM, Cheung CK, Lau GK, Fan ST, Wong J. Identification of hepatitis B virus-specific lymphocytes in human liver grafts from HBV-immune donors. Liver Transpl. 2007 13 : 71 9.
62. Buti M, Mas A, Prieto M et al. A randomized study comparing lamivudine monotherapy after a short course of hepatitis B immune globulin (HBIg) and lamivudine with long-term lamivudine plus HBIg in the prevention of hepatitis B virus recurrence after liver transplantation. J. Hepatol. 2003 38 : 811 817.
63. Dodson SF, De Vera ME, Bonham CA, Geller DA, Rakela J, Fung JJ. Lamivudine after hepatitis B immune globulin is effective in preventing hepatitis B recurrence after liver transplantation. Liver Transpl. 2000 6 : 434 439.
64. Angus PW, Patterson SJ, Strasser SI, McCaughan GW, Gane E. A randomized study of adefovir dipivoxil in place of HBIG in combination with lamivudine as post-liver transplantation hepatitis B prophylaxis. Hepatology 2008 48 : 1460 1466.
65. Neff GW, Kemmer N, Kaiser TE et al. Combination therapy in liver transplant recipients with hepatitis B virus without hepatitis B immune globulin. Dig. Dis. Sci. 2007 52 : 2497 2500.
66. Nath DS, Kalis A, Nelson S, Payne WD, Lake JR, Humar A. Hepatitis B prophylaxis post-liver transplant without maintenance hepatitis B immunoglobulin therapy. Clin. Transplant. 2006 2 : 206 210.
67. Rosenau J, Hooman N, Rifai K et al. Hepatitis B virus immunization with an adjuvant containing vaccine after liver transplantation for hepatitis B-related disease: failure of humoral and cellular immune response. Transpl. Int. 2006 19 : 828 833.
68. Rosenau J, Hooman N, Hadem J et al. Failure of hepatitis B vaccination with conventional HBsAg vaccine in patients with continuous HBIG prophylaxis after liver transplantation. Liver Transpl. 2007 13 : 367 373.